Summary & Overview
HCPCS Level II J9376: Pozelimab-bbfg Injection, 1 mg
HCPCS Level II code J9376 identifies the injectable biologic pozelimab-bbfg, billed per 1 mg. This code matters nationally as it standardizes reporting and reimbursement for a specific targeted therapy administered via injection, enabling consistent billing across outpatient infusion centers, physician offices, and hospital outpatient departments. Accurate use of J9376 supports provider reimbursement, payer adjudication, and utilization tracking for a high-cost biologic.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing benchmarks, common modifiers in practice, and clinical context relevant to the drug’s administration.
Readers will learn: the clinical and billing definition of J9376; typical sites of service and service type; payer coverage considerations and where to find policy updates; standard billing practices and frequently used modifiers; and contextual information useful for coding accuracy and claims processing. Data not available in the input is noted where applicable. This summary is written for a national audience and focuses on coding clarity, payer considerations, and operational context for providers and billing professionals.
Billing Code Overview
HCPCS Level II code J9376 represents the injection product pozelimab-bbfg, billed per 1 mg. This code is used to report administration of the specified biologic drug.
-
Service type: Injectable biologic drug administration
-
Typical site of service: Infusion center, outpatient hospital department, or physician office
Clinical & Coding Specifications
Clinical Context
A typical scenario involves an adult patient with a complement-mediated disorder for which pozelimab-bbfg is indicated (for example, a rare complement C5-mediated disease). A specialist (hematologist, immunologist, or nephrologist) prescribes intravenous administration of J9376 (pozelimab-bbfg) dosed in milligrams; the facility schedules an infusion visit in an outpatient infusion center or hospital outpatient department. Prior to infusion the clinical team verifies indications, recent labs (CBC, renal function), vital signs, and allergy history, obtains informed consent, and documents baseline symptoms. Nursing prepares the calculated dose drawn from the single-use vial and performs standard intravenous access and administration per product labeling, monitoring for infusion reactions during and for a period after infusion. Documentation includes drug name and dose in mg, lot number, route, date and time of administration, infusion duration, premedications if given, and any adverse events. Billing uses the HCPCS level II code J9376 reported in units corresponding to milligrams administered, with appropriate modifier(s) to indicate payer-specific circumstances or service details. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or physician offices with infusion capabilities. Common clinical workflow steps: referral/prescription, prior authorization, pre-infusion assessment and labs, infusion administration and monitoring, post-infusion documentation and discharge instructions, and periodic follow-up for effectiveness and safety monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|